These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 14696430

  • 1. Innovative chemotherapies for stage III colon cancer: a cost-effectiveness study.
    Koperna T, Semmler D.
    Hepatogastroenterology; 2003; 50(54):1903-9. PubMed ID: 14696430
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US.
    Aballéa S, Chancellor JV, Raikou M, Drummond MF, Weinstein MC, Jourdan S, Bridgewater J.
    Cancer; 2007 Mar 15; 109(6):1082-9. PubMed ID: 17265519
    [Abstract] [Full Text] [Related]

  • 3. Comparative and cost-effectiveness of oxaliplatin-based or irinotecan-based regimens compared with 5-fluorouracil/leucovorin alone among US elderly stage IV colon cancer patients.
    Mullins CD, Hsiao FY, Onukwugha E, Pandya NB, Hanna N.
    Cancer; 2012 Jun 15; 118(12):3173-81. PubMed ID: 22020739
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma.
    Hillner BE, Schrag D, Sargent DJ, Fuchs CS, Goldberg RM.
    Cancer; 2005 Nov 01; 104(9):1871-84. PubMed ID: 16177989
    [Abstract] [Full Text] [Related]

  • 5. Pharmacoeconomic analysis of capecitabine versus 5-fluorouracil/leucovorin as adjuvant therapy for stage III colon cancer in Taiwan.
    Hsu TC, Chen HH, Yang MC, Wang HM, Chuang JH, Jao SW, Chiang HC, Wen CY, Tseng JH, Chen LT.
    Value Health; 2011 Nov 01; 14(5):647-51. PubMed ID: 21839401
    [Abstract] [Full Text] [Related]

  • 6. Is oxaliplatin combined with weekly bolus 5-fluorouracil and leucovorin an option for stage II and III colon cancer?
    Twelves C.
    Nat Clin Pract Oncol; 2008 Feb 01; 5(2):72-3. PubMed ID: 18030299
    [No Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness of adjuvant FOLFOX therapy for stage III colon cancer in Japan based on the MOSAIC trial.
    Shiroiwa T, Takeuchi T, Fukuda T, Shimozuma K, Ohashi Y.
    Value Health; 2012 Feb 01; 15(2):255-60. PubMed ID: 22433756
    [Abstract] [Full Text] [Related]

  • 8. A Markov model assessing the effectiveness and cost-effectiveness of FOLFOX compared with FOLFIRI for the initial treatment of metastatic colorectal cancer.
    Tumeh JW, Shenoy PJ, Moore SG, Kauh J, Flowers C.
    Am J Clin Oncol; 2009 Feb 01; 32(1):49-55. PubMed ID: 19194125
    [Abstract] [Full Text] [Related]

  • 9. An economic evaluation of oxaliplatin for the adjuvant treatment of colon cancer in the United Kingdom (UK).
    Aballéa S, Boler A, Craig A, Wasan H.
    Eur J Cancer; 2007 Jul 01; 43(11):1687-93. PubMed ID: 17587564
    [Abstract] [Full Text] [Related]

  • 10. Oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX-4) as salvage chemotherapy in patients with pretreated colorectal cancer.
    Shitara K, Munakata M, Muto O, Kasai M, Okada R, Mitobe S, Sakata Y.
    Gan To Kagaku Ryoho; 2007 Jul 01; 34(7):1079-84. PubMed ID: 17637544
    [Abstract] [Full Text] [Related]

  • 11. Practical outcome of adjuvant FOLFOX4 chemotherapy in elderly patients with stage III colon cancer: single-center study in Korea.
    Kim JY, Kim YJ, Lee KW, Lee JS, Kim DW, Kang SB, Lee HS, Jang NY, Kim JS, Kim JH.
    Jpn J Clin Oncol; 2013 Feb 01; 43(2):132-8. PubMed ID: 23204187
    [Abstract] [Full Text] [Related]

  • 12. Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5-fluorouracil/leucovorin plus or minus oxaliplatin: a prospective analysis.
    Kuebler JP, Colangelo L, O'Connell MJ, Smith RE, Yothers G, Begovic M, Robinson B, Seay TE, Wolmark N.
    Cancer; 2007 Nov 01; 110(9):1945-50. PubMed ID: 17853393
    [Abstract] [Full Text] [Related]

  • 13. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07.
    Land SR, Kopec JA, Cecchini RS, Ganz PA, Wieand HS, Colangelo LH, Murphy K, Kuebler JP, Seay TE, Needles BM, Bearden JD, Colman LK, Lanier KS, Pajon ER, Cella D, Smith RE, O'Connell MJ, Costantino JP, Wolmark N.
    J Clin Oncol; 2007 Jun 01; 25(16):2205-11. PubMed ID: 17470850
    [Abstract] [Full Text] [Related]

  • 14. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?
    Gill S, Loprinzi CL, Sargent DJ, Thomé SD, Alberts SR, Haller DG, Benedetti J, Francini G, Shepherd LE, Francois Seitz J, Labianca R, Chen W, Cha SS, Heldebrant MP, Goldberg RM.
    J Clin Oncol; 2004 May 15; 22(10):1797-806. PubMed ID: 15067028
    [Abstract] [Full Text] [Related]

  • 15. Cost-minimization analysis of sequence changes between FOLFIRI and FOLFOX6 therapy for advanced colorectal cancer in Japan.
    Miyazaki Y, Harada T, Akase T, Arakawa I, Inoue T.
    Clin Ther; 2009 May 15; 31 Pt 2():2433-41. PubMed ID: 20110051
    [Abstract] [Full Text] [Related]

  • 16. Economic impact of simplified de Gramont regimen in first-line therapy in metastatic colorectal cancer.
    Limat S, Bracco-Nolin CH, Legat-Fagnoni C, Chaigneau L, Stein U, Huchet B, Pivot X, Woronoff-Lemsi MC.
    Eur J Health Econ; 2006 Jun 15; 7(2):107-13. PubMed ID: 16474968
    [Abstract] [Full Text] [Related]

  • 17. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06.
    Lembersky BC, Wieand HS, Petrelli NJ, O'Connell MJ, Colangelo LH, Smith RE, Seay TE, Giguere JK, Marshall ME, Jacobs AD, Colman LK, Soran A, Yothers G, Wolmark N.
    J Clin Oncol; 2006 May 01; 24(13):2059-64. PubMed ID: 16648506
    [Abstract] [Full Text] [Related]

  • 18. Adjuvant therapy of colon cancer: current status and future directions.
    Chung KY, Saltz LB.
    Cancer J; 2007 May 01; 13(3):192-7. PubMed ID: 17620769
    [Abstract] [Full Text] [Related]

  • 19. Adjuvant chemotherapy of colon cancer: lymph node involvement without metastases.
    Prescrire Int; 2006 Jun 01; 15(83):109-1. PubMed ID: 16764102
    [Abstract] [Full Text] [Related]

  • 20. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
    Kemeny N, Garay CA, Gurtler J, Hochster H, Kennedy P, Benson A, Brandt DS, Polikoff J, Wertheim M, Shumaker G, Hallman D, Burger B, Gupta S.
    J Clin Oncol; 2004 Dec 01; 22(23):4753-61. PubMed ID: 15570076
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.